Treatment of toxoplasmosis: historical perspective, animal models, and current clinical practice

IR Dunay, K Gajurel, R Dhakal… - Clinical microbiology …, 2018 - journals.asm.org
Primary Toxoplasma gondii infection is usually subclinical, but cervical lymphadenopathy or
ocular disease can be present in some patients. Active infection is characterized by …

Treatment of toxoplasmosis: Current options and future perspectives

N Konstantinovic, H Guegan, T Stäjner, S Belaz… - Food and waterborne …, 2019 - Elsevier
Toxoplasmosis is a worldwide parasitic disease infecting about one third of humans, with
possible severe outcomes in neonates and immunocompromised patients. Despite …

Drug Resistance in Toxoplasma gondii

M Montazeri, S Mehrzadi, M Sharif, S Sarvi… - Frontiers in …, 2018 - frontiersin.org
Toxoplasma gondii (T. gondii) is a global protozoan parasite infecting up to one-third of the
world population. Pyrimethamine (PYR) and sulfadiazine (SDZ) are the most widely used …

Comprehensive Overview of Toxoplasma gondii-Induced and Associated Diseases

D Daher, A Shaghlil, E Sobh, M Hamie, ME Hassan… - Pathogens, 2021 - mdpi.com
Toxoplasma gondii (T. gondii) is a prevalent protozoan parasite of medical and veterinary
significance. It is the etiologic agent of toxoplasmosis, a neglected disease in which …

Transferable mechanisms of quinolone resistance from 1998 onward

J Ruiz - Clinical microbiology reviews, 2019 - journals.asm.org
While the description of resistance to quinolones is almost as old as these antimicrobial
agents themselves, transferable mechanisms of quinolone resistance (TMQR) remained …

[HTML][HTML] Inonotus obliquus–from folk medicine to clinical use

KA Szychowski, B Skóra, T Pomianek… - Journal of traditional and …, 2021 - Elsevier
The Inonotus obliquus (I. obliquus) mushroom was traditionally used to treat various
gastrointestinal diseases. For many years, mounting evidence has indicated the potential of …

[HTML][HTML] Toxoplasmosis: Current and emerging parasite druggable targets

RE Hajj, L Tawk, S Itani, M Hamie, J Ezzeddine… - Microorganisms, 2021 - mdpi.com
Toxoplasmosis is a prevalent disease affecting a wide range of hosts including
approximately one-third of the human population. It is caused by the sporozoan parasite …

Prospects of halofuginone as an antiprotozoal drug scaffold

J Gill, A Sharma - Drug discovery today, 2022 - Elsevier
Highlights•The global prevalence of parasitic protozoan diseases remains a significant
public health challenge.•Halofuginone, a plant-derived compound, has beneficial roles in …

Management of toxoplasmosis in transplant recipients: an update

C Dard, P Marty, MP Brenier-Pinchart… - Expert review of anti …, 2018 - Taylor & Francis
Introduction. Toxoplasmosis is a life-threatening parasitic disease for hematopoietic stem
cell transplant (HSCT) and solid organ transplant (SOT) recipients. The risk of toxoplasmosis …

Global Status of Toxoplasma gondii Seroprevalence in Rodents: A Systematic Review and Meta-Analysis

TM Galeh, S Sarvi, M Montazeri… - Frontiers in Veterinary …, 2020 - frontiersin.org
Toxoplasmosis is one of the most prevalent infections in humans and animals caused by the
intracellular protozoan parasite Toxoplasma gondii (T. gondii). Rodents, as intermediate and …